The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Subscribe To Our Newsletter & Stay Updated
